Vhcp Management buys $1.4 Million stake in Global Blood Therapeutics Inc (GBT)

Global Blood Therapeutics Inc (GBT) : Vhcp Management scooped up 12,299 additional shares in Global Blood Therapeutics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 13, 2016. The investment management firm now holds a total of 72,990 shares of Global Blood Therapeutics Inc which is valued at $1.4 Million.Global Blood Therapeutics Inc makes up approximately 1.30% of Vhcp Management’s portfolio.

Other Hedge Funds, Including , Sabby Management reduced its stake in GBT by selling 205,857 shares or 60.04% in the most recent quarter. The Hedge Fund company now holds 137,000 shares of GBT which is valued at $2.6 Million. Global Blood Therapeutics Inc makes up approx 0.91% of Sabby Management’s portfolio. Group One Trading added GBT to its portfolio by purchasing 3,369 company shares during the most recent quarter which is valued at $64,887. Global Blood Therapeutics Inc makes up approx 0.01% of Group One Trading’s portfolio.Blackrock Advisors boosted its stake in GBT in the latest quarter, The investment management firm added 1,042 additional shares and now holds a total of 3,455 shares of Global Blood Therapeutics Inc which is valued at $66,543.Blackrock Group Ltd boosted its stake in GBT in the latest quarter, The investment management firm added 1,197 additional shares and now holds a total of 2,289 shares of Global Blood Therapeutics Inc which is valued at $44,086.Casdin Capital boosted its stake in GBT in the latest quarter, The investment management firm added 40,000 additional shares and now holds a total of 105,000 shares of Global Blood Therapeutics Inc which is valued at $2 Million. Global Blood Therapeutics Inc makes up approx 2.48% of Casdin Capital’s portfolio.

On the company’s financial health, Global Blood Therapeutics Inc reported $-0.56 EPS for the quarter, missing the analyst consensus estimate by $ -0.08 based on the information available during the earnings call on May 12, 2016. Analyst had a consensus of $-0.48.During the same quarter in the previous year, the company posted $-4.22 EPS.

Many Wall Street Analysts have commented on Global Blood Therapeutics Inc. Shares were Reiterated by Wedbush on Mar 2, 2016 to “Outperform” and Lowered the Price Target to $ 66 from a previous price target of $94 .

Global Blood Therapeutics Inc. is a biopharmaceutical company that engages in discovering developing and commercializing therapeutics to treat blood-based disorders. The Company is engaged in developing initial product candidate GBT440 oral prophylactic therapy for sickle cell disease (SCD). The Company offers randomized placebo-controlled double-blind single and multiple ascending dose Phase 1/2 clinical trial of GBT440 in healthy subjects and patients with SCD. It is also developing hemoglobin modifiers for pulmonary disorders such as acute respiratory distress syndrome in which increased oxygen delivery is needed. The Company through its GBT440 or analog also focuses on chemical and biological mechanisms of blood-based disorders to target hypoxemic pulmonary disorders and hereditary angioedema (HAE) which is in pre-clinical trials. In addition the Company develops TBD an oral kallikrein inhibitor which are in Phase 1/2 clinical trials.

Leave a Reply

Global Blood Therapeutics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Global Blood Therapeutics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.